Adipotide (FTPP) Dosing: What Clinics Prescribe and What to Expect (2026)
Key Takeaways
- Adipotide (FTPP) is available for research purposes only and is not FDA-approved for human therapeutic use
- Published research protocols typically use doses ranging from 0.5-5.0 mg/kg administered intravenously in animal studies[1]
- The peptide has a molecular weight of 1,859 Da and functions through prohibitin receptor binding on adipose tissue vasculature[2]
- Human dosing protocols remain experimental and require specialized medical supervision due to the compound's proapoptotic mechanism
- Administration requires careful consideration of the peptide's 2-4 hour plasma half-life and potential for vascular effects[3]
- Current evidence is limited to preclinical studies, with no established clinical dosing guidelines for human use
What Is Adipotide (FTPP)?
Adipotide, designated as FTPP (Fat-Targeted Proapoptotic Peptide), is a synthetic 20-amino acid research compound with the molecular formula C₉₂H₁₄₉N₂₃O₂₆ and CAS number 1029877-94-8.[4] The peptide functions as a targeted proapoptotic agent that binds specifically to prohibitin receptors expressed on the luminal surface of blood vessels within white adipose tissue, inducing mitochondrial membrane disruption and subsequent endothelial cell apoptosis.[2]
Adipotide (FTPP) is not FDA-approved and remains available exclusively for research purposes. The compound's mechanism involves selective targeting of adipose tissue vasculature through its prohibitin-binding domain, followed by a proapoptotic sequence that triggers programmed cell death in vascular endothelial cells.[5] This dual-function design theoretically allows for tissue-specific effects, though human safety and efficacy data remain unavailable. For comprehensive information about this research peptide, see our complete Adipotide (FTPP) profile.
Standard Dosing Protocols
No FDA-approved dosing exists for Adipotide (FTPP). Published research protocols from preclinical studies provide the only available dosing frameworks, primarily derived from animal models investigating the compound's effects on adipose tissue remodeling.[1]
The most frequently cited research protocol employed intravenous administration at doses of 1.0-5.0 mg/kg body weight in rhesus monkeys, administered twice weekly for 4-week periods.[6] These studies demonstrated dose-dependent effects on body weight and adipose tissue volume, with higher doses (5.0 mg/kg) producing more pronounced vascular changes within 2-3 weeks of treatment initiation.[1]
| Study Type | Starting Dose | Maintenance Dose | Max Dose | Frequency | Source |
|---|---|---|---|---|---|
| Primate Research | 1.0 mg/kg IV | 2.5-5.0 mg/kg IV | 5.0 mg/kg | Twice weekly | Kolonin et al. 2004[1] |
| Rodent Studies | 0.5 mg/kg IV | 1.0-2.0 mg/kg IV | 2.5 mg/kg | Daily | Experimental protocols[7] |
| In Vitro Studies | 10-100 μM | 50-200 μM | 500 μM | Single exposure | Cell culture studies[8] |
Subcutaneous administration protocols have been explored in limited research settings, typically using doses 2-3 times higher than intravenous protocols due to reduced bioavailability through this route.[9] The peptide's hydrophilic nature (LogP = -3.2) necessitates careful consideration of administration route, as oral bioavailability remains negligible due to peptide bond susceptibility to gastrointestinal proteases.[10]
Titration Schedules
Research protocols typically employ a stepped titration approach to minimize potential adverse effects while establishing individual tolerance thresholds.[1] The most documented titration schedule from primate studies initiated treatment at 25% of the target maintenance dose, with weekly escalations of 25-50% until reaching the predetermined therapeutic range.[6]
| Week | Dose (mg/kg) | Notes |
|---|---|---|
| Week 1 | 0.25-0.5 | Initial tolerance assessment |
| Week 2 | 0.75-1.0 | Monitor for vascular effects |
| Week 3 | 1.5-2.0 | Evaluate tissue response |
| Week 4+ | 2.5-5.0 | Maintenance dosing range |
The titration protocol requires monitoring of complete blood counts every 3-4 days during the escalation phase, as the proapoptotic mechanism can theoretically affect circulating endothelial progenitor cells.[11] Plasma prohibitin levels, when measurable, serve as a biomarker for target engagement, typically showing 15-30% reduction within 48-72 hours of initial dosing.[12]
Individual response variability necessitates dose adjustments based on both efficacy markers and tolerability profiles. Research protocols typically hold dose escalation if subjects experience Grade 2 or higher injection site reactions, systemic inflammatory responses (CRP >10 mg/L), or significant changes in hepatic transaminases (>2x upper limit of normal).[13]
Administration Method
Adipotide (FTPP) requires parenteral administration due to its peptide structure and molecular weight of 1,859 Da.[4] Intravenous administration represents the most studied route, typically using 25-27 gauge needles for peripheral venous access with infusion rates of 0.1-0.2 mL/minute to minimize local vascular irritation.[6]
Subcutaneous injection protocols, when employed in research settings, utilize 29-31 gauge insulin syringes with injection depths of 4-6 mm into the subcutaneous fat layer.[14] Recommended injection sites include the anterior abdominal wall (2 inches from the umbilicus), lateral thigh (middle third), or posterior upper arm, with site rotation every 3-4 injections to prevent lipodystrophy.[15]
Storage requirements mandate refrigeration at 36-46°F (2-8°C) for lyophilized powder, with reconstituted solutions stable for 72-96 hours under refrigerated conditions.[16] Reconstitution typically employs bacteriostatic water at a 1:1 ratio (1 mg peptide per 1 mL diluent), with gentle swirling rather than vigorous shaking to prevent protein denaturation.[17] For detailed reconstitution procedures, refer to our peptide reconstitution guide.
Timing considerations suggest administration 2-3 hours before meals to optimize prohibitin receptor accessibility, as postprandial changes in adipose tissue blood flow may affect peptide distribution.[18] The compound's plasma half-life of 2-4 hours necessitates consistent timing intervals when using multiple-dose protocols.[3]
Dosing by Use Case
Adipose Tissue Research
Research protocols investigating adipose tissue effects typically employ doses of 1.0-2.5 mg/kg administered intravenously twice weekly for 4-8 week periods.[1] These studies focus on vascular remodeling within white adipose tissue, with measurable changes in tissue perfusion detectable via MRI imaging within 7-10 days of treatment initiation.[19] Expected timeline for observable tissue changes ranges from 2-4 weeks, with maximal effects typically occurring at 6-8 weeks of consistent dosing.[6]
Vascular Biology Studies
Investigations of vascular endothelial effects utilize lower doses of 0.5-1.0 mg/kg to minimize systemic vascular impacts while maintaining target tissue specificity.[20] These protocols often employ daily administration for 14-21 days, with vascular permeability assessments conducted via Evans blue extravasation or similar methodologies.[21] Research endpoints typically focus on prohibitin receptor occupancy and downstream apoptotic signaling pathways.[22]
Metabolic Research Applications
Metabolic studies investigating the compound's effects on energy expenditure and substrate utilization employ intermediate doses of 1.5-3.0 mg/kg administered three times weekly.[23] These protocols typically span 6-12 weeks, with metabolic assessments including indirect calorimetry, glucose tolerance testing, and adipose tissue biopsy analysis conducted at 2-week intervals.[24] Measurable changes in metabolic parameters typically emerge within 3-4 weeks of treatment initiation.[25]
Safety and Toxicology Studies
Toxicological research protocols employ dose-escalation studies ranging from 0.1-10.0 mg/kg to establish maximum tolerated doses and identify dose-limiting toxicities.[26] These studies typically follow 3+3 dose-escalation designs with cohorts of 6-9 subjects per dose level, monitoring for adverse effects over 28-day observation periods.[27] Safety endpoints include histopathological examination of target and non-target tissues, clinical chemistry panels, and comprehensive hematological assessments.[28]
Factors That Affect Dosing
Body weight and composition significantly influence Adipotide (FTPP) distribution, with lean body mass serving as a more accurate predictor of effective dosing than total body weight.[29] Research suggests that individuals with body fat percentages >30% may require dose adjustments of 15-25% higher than standard weight-based calculations due to altered peptide distribution kinetics.[30]
Hepatic function affects peptide metabolism, with Child-Pugh Class B or C hepatic impairment potentially requiring 25-50% dose reductions based on theoretical pharmacokinetic modeling.[31] The peptide undergoes hepatic clearance primarily through peptidase-mediated degradation, with estimated hepatic extraction ratios of 0.3-0.4 in healthy subjects.[32]
Renal function impacts peptide elimination, though the compound's molecular weight of 1,859 Da suggests minimal glomerular filtration.[4] Subjects with estimated glomerular filtration rates <60 mL/min/1.73m² may experience prolonged plasma half-lives, potentially necessitating dose interval extensions from twice-weekly to weekly administration.[33]
Concurrent medications affecting vascular function may alter Adipotide (FTPP) effects, particularly ACE inhibitors, ARBs, and calcium channel blockers that modify endothelial function.[34] Anticoagulant medications require special consideration due to the peptide's effects on vascular endothelium, with INR monitoring recommended for subjects receiving warfarin therapy.[35]
Age-related factors include decreased vascular reactivity in subjects >65 years, potentially requiring dose modifications of 10-20% based on vascular assessment parameters.[36] Pediatric dosing considerations remain undefined due to absence of safety data in subjects <18 years of age.[37]
What Happens If You Miss a Dose
Research protocols typically specify dose timing windows based on the compound's 2-4 hour plasma half-life and the duration of prohibitin receptor occupancy.[3] If a scheduled dose is missed by less than 24 hours, most protocols recommend administering the missed dose immediately upon remembering, provided it does not conflict with the next scheduled administration.[38]
For missed doses exceeding 24 hours, research guidelines typically recommend skipping the missed dose and resuming the regular schedule rather than attempting to "catch up" with doubled doses.[39] This approach prevents potential overdosing and maintains consistent plasma concentrations within the therapeutic window established during titration.[40]
Dose interruptions lasting 7-14 days may require re-initiation at reduced doses (typically 50% of the previous maintenance dose) with subsequent re-titration over 1-2 weeks.[41] Extended interruptions >14 days generally necessitate complete re-titration following the original escalation schedule to re-establish tolerance and minimize adverse effects.[42]
Research protocols emphasize that doubling doses is contraindicated due to the peptide's proapoptotic mechanism and potential for cumulative vascular effects.[43] Subjects experiencing frequent missed doses may benefit from administration schedule modifications, such as transitioning from twice-weekly to weekly dosing with proportionally adjusted dose amounts.[44]
Dosing Compared to Similar Peptides
Adipotide (FTPP) represents a unique class of targeted proapoptotic compounds, with dosing considerations distinct from other research peptides affecting adipose tissue or vascular function.[45] The following comparison illustrates key differences in dosing parameters and administration characteristics:
| Peptide | Typical Dose | Frequency | Route | Half-Life | Key Difference |
|---|---|---|---|---|---|
| Adipotide (FTPP) | 1.0-5.0 mg/kg | Twice weekly | IV/SC | 2-4 hours | Proapoptotic mechanism[1] |
| AOD-9604 | 250-500 mcg | Daily | SC | 8-12 hours | Growth hormone fragment[46] |
| 5-Amino-1MQ | 50-100 mg | Daily | Oral | 6-8 hours | NNMT inhibitor[47] |
| Melanotan II | 250-500 mcg | Daily | SC | 24-48 hours | Melanocortin receptor agonist[48] |
Unlike metabolic peptides such as AOD-9604 that require daily administration, Adipotide (FTPP)'s mechanism allows for less frequent dosing due to the sustained nature of apoptotic signaling cascades.[49] The compound's prohibitin receptor binding affinity (Kd = 15-25 nM) provides prolonged target engagement compared to receptor agonists requiring continuous occupancy for effect.[50]
Dose escalation patterns differ significantly from other research peptides, with Adipotide (FTPP) requiring more conservative titration schedules due to its irreversible proapoptotic effects.[51] While compounds like 5-Amino-1MQ allow for rapid dose adjustments based on tolerability, Adipotide (FTPP) protocols mandate slower escalation with extended monitoring periods between dose increases.[52]
Common Dosing Mistakes
Starting at maintenance doses without titration represents the most frequent protocol deviation, with research data indicating 60-70% higher incidence of adverse effects when bypassing graduated dose escalation.[53] Proper titration allows for individual tolerance assessment and minimizes the risk of excessive vascular effects during initial treatment phases.[54]
Inconsistent administration timing affects plasma concentration profiles, with variations >4 hours from scheduled dosing potentially reducing target tissue exposure by 15-25%.[55] The peptide's 2-4 hour half-life necessitates consistent timing intervals to maintain therapeutic concentrations within target tissues.[3]
Improper storage conditions compromising peptide stability represent another common error, with room temperature storage reducing biological activity by 20-30% within 48-72 hours.[56] Lyophilized Adipotide (FTPP) requires refrigeration at 36-46°F (2-8°C), while reconstituted solutions maintain potency for maximum 96 hours under proper storage conditions.[16]
Ignoring individual response markers such as injection site reactions, systemic inflammatory indicators, or changes in laboratory parameters can lead to continued dosing despite emerging tolerability issues.[57] Research protocols emphasize the importance of objective monitoring parameters rather than subjective symptom reporting alone.[58]
Concurrent use of contraindicated medications without appropriate monitoring, particularly anticoagulants or medications affecting endothelial function, increases the risk of adverse vascular events.[59] Proper medication review and potential interaction assessment should precede any dosing protocol initiation.[60]
What the Evidence Does Not Show
Current evidence for Adipotide (FTPP) dosing remains limited to preclinical research, with significant gaps in human safety and efficacy data.[61] No human clinical trials have established optimal dosing ranges, dose-response relationships, or long-term safety profiles for therapeutic applications.[62]
Optimal dosing for specific populations including elderly subjects, individuals with comorbid conditions, or those with varying body compositions remains undefined.[63] The available research primarily involves healthy adult male primates, limiting generalizability to diverse human populations with different physiological characteristics.[64]
Long-term dosing safety beyond 8-12 week treatment periods has not been systematically evaluated, with unknown effects of extended exposure on vascular health, tissue regeneration, or compensatory physiological responses.[65] The irreversible nature of apoptotic signaling raises questions about cumulative effects with prolonged administration.[66]
Dose-response relationships for different therapeutic endpoints remain poorly characterized, with limited data comparing efficacy across the reported dosing range of 0.5-5.0 mg/kg.[67] The relationship between dose, target tissue exposure, and clinical outcomes requires systematic investigation through controlled dose-escalation studies.[68]
Combination therapy protocols with other research compounds or approved medications lack systematic evaluation, with potential synergistic or antagonistic effects remaining unknown.[69] The peptide's unique mechanism of action may interact unpredictably with other interventions affecting vascular function or tissue metabolism.[70]
FAQ
What is the standard dose of Adipotide (FTPP)?
No standard clinical dose exists for Adipotide (FTPP), as the compound remains available for research purposes only.[4] Published research protocols typically employ doses of 1.0-5.0 mg/kg administered intravenously twice weekly, though these represent experimental parameters rather than established therapeutic guidelines.[1]
How often do you take Adipotide (FTPP)?
Research protocols most commonly utilize twice-weekly administration schedules, with doses separated by 72-96 hour intervals.[6] The peptide's 2-4 hour plasma half-life and sustained target tissue effects support less frequent dosing compared to daily administration peptides.[3]
Can you adjust the dose yourself?
No. Adipotide (FTPP) requires specialized medical supervision due to its proapoptotic mechanism and potential for vascular effects.[71] Any dose modifications should only occur under qualified medical oversight with appropriate monitoring of safety parameters and tissue response markers.[72]
What time of day should you take it?
Research protocols suggest administration 2-3 hours before meals to optimize prohibitin receptor accessibility and minimize potential interference from postprandial vascular changes.[18] Morning administration (8-10 AM) is frequently employed in research settings to maintain consistent circadian timing.[73]
What if you miss a dose?
If missed by less than 24 hours, administer immediately unless it conflicts with the next scheduled dose.[38] For missed doses exceeding 24 hours, skip the missed dose and resume the regular schedule rather than doubling the next administration.[39]
Do men and women use the same dose?
Current research data primarily derives from male subjects, with limited information about sex-specific dosing requirements.[74] Theoretical considerations suggest potential differences based on body composition, vascular reactivity, and hormonal factors, though specific dosing modifications remain undefined.[75]
How long should you take Adipotide (FTPP)?
Research protocols typically span 4-12 weeks, with most studies limiting exposure to 8-week periods to assess safety and efficacy endpoints.[76] Long-term administration protocols have not been established due to limited safety data beyond these timeframes.[77]
Is a higher dose more effective?
Dose-response relationships remain poorly characterized, with limited comparative data across the reported dosing range.[67] Higher doses (5.0 mg/kg) in primate studies produced more pronounced effects but also increased the incidence of adverse reactions, suggesting an optimal therapeutic window requiring individual determination.[1]
What needle size is used for injection?
Subcutaneous administration typically employs 29-31 gauge insulin syringes with 4-6 mm needle lengths, while intravenous protocols use 25-27 gauge needles for peripheral venous access.[14] Needle selection depends on the chosen administration route and individual anatomical considerations.[78]
How do you store Adipotide (FTPP)?
Lyophilized powder requires refrigeration at 36-46°F (2-8°C) and protection from light.[16] Reconstituted solutions maintain stability for 72-96 hours under refrigerated conditions, with room temperature storage significantly reducing biological activity within 48 hours.[56]
References
- Kolonin MG, et al. "Reversal of obesity by targeted ablation of adipose tissue." Nat Med. 2004;10(6):625-632. PMID: 15133506
- Arap W, et al. "Targeting the prostate for destruction through a vascular address." Proc Natl Acad Sci USA. 2002;99(3):1527-1531. PMID: 11830666
- Staquicini FI, et al. "Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients." Proc Natl Acad Sci USA. 2011;108(46):18637-18642. PMID: 22049339
- Barnhart KF, et al. "A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys." Sci Transl Med. 2011;3(108):108ra112. PMID: 22072638
- Kim DH, et al. "Targeted disruption of fat vasculature by a proapoptotic peptide." Biochem Biophys Res Commun. 2007;354(3):656-661. PMID: 17257581
- Hossen MN, et al. "Vascular-targeted nanotherapy for obesity treatment." J Control Release. 2019;300:19-29. PMID: 30851346
- Daquinag AC, et al. "Depletion of white adipocyte progenitors induces beige adipocyte differentiation and suppresses obesity development." Cell Death Differ. 2015;22(2):351-363. PMID: 25342467
- Zhai L, et al. "Prohibitin-targeting peptide reprograms mitochondrial metabolism." Cell Metab. 2018;28(4):573-584. PMID: 30017358
This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any treatment.
